Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeuti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Case Rep
Main Authors: Alderuccio, Juan Pablo, Desai, Amrita, Yepes, Monica M., Chapman, Jennifer R., Vega, Francisco, Lossos, Izidore S.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Case Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889253/
https://ncbi.nlm.nih.gov/pubmed/29636930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1382
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki